Immunotherapy combo shows promise against rare throat cancer
Disease control
Completed
This phase II trial tested whether adding the immunotherapy drug nivolumab (Opdivo) to standard chemoradiation helps treat stage II-IVB nasopharyngeal carcinoma, a type of throat cancer. Forty patients received nivolumab infusions every two weeks alongside cisplatin chemotherapy …
Phase: PHASE2 • Sponsor: Sue Yom • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC